Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Risk Factors for the Development of Cutaneous Melanoma after Allogeneic Hematopoietic Cell Transplantation

Megan Herr, PhD, Rochelle E. Curtis, Margaret A. Tucker, Heather R. Tecca, Eric A. Engels, MD MPH, Elizabeth Cahoon, Minoo Battiwalla, MD, David K. Buchbinder, MD MSHS, Mary E. D. Flowers, MD, Ruta Brazauskas, PhD, Bronwen E. Shaw, MD PhD, Lindsay M. Morton, PhD

Blood (2018) 132 (Supplement 1): 249.

https://doi.org/10.1182/blood-2018-99-116261

Published: 2018

Journal Articles

Patterns of Cutaneous Malignancy Risk Among Survivors of Non-Hodgkin Lymphoma Subtypes

Lindsay M Morton, PhD, Megan M Herr, PhD, Sara J. Schonfeld, PhD, Graca M Dores, MD MPH, Rochelle E Curtis, MA, Margaret A. Tucker, MD

Blood (2016) 128 (22): 4771.

https://doi.org/10.1182/blood.V128.22.4771.4771

Published: 2016

Journal Articles

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

Youn H Kim, MD, Sean Whittaker, MB, ChB, FRCP, MD, Steven M Horwitz, MD, Madeleine Duvic, MD, Reinhard Dummer, MD, Julia J Scarisbrick, MBChB FRCP MD, Pietro Quaglino, MD, Pier Luigi Zinzani, MD PhD, Pascal Wolter, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Erin Zagadailov, PharmD, MS, William L Trepicchio, PhD, Yi Liu, PhD, Meredith Little, MPH, H Miles Prince, MD

Blood (2016) 128 (22): 182.

https://doi.org/10.1182/blood.V128.22.182.182

Published: 2016

Journal Articles

Role Of Long Pentraxin 3 (PTX3) In Wound Closure Induced By Bone Marrow-Derived Mesenchymal Stromal Cells

Claudia Cappuzzello, Andrea Doni, Erica Dander, Fabio Pasqualini, Manuela Nebuloni, Barbara Bottazzi, Alberto Mantovani, Andrea Biondi, MD, Cecilia Garlanda, Giovanna D'Amico

Blood (2013) 122 (21): 1220.

https://doi.org/10.1182/blood.V122.21.1220.1220

Published: 2013

Journal Articles

A Single Center Experience With Pralatrexate Alone Or In Combination With Bexarotene: Long Term Responses In Advanced Stage Relapsed/Refractory Cutaneous T-Cell Lymphoma

Rakhshandra Talpur, MD, Andrew Thompson, Pamela Gangar, Madeleine Duvic, MD

Blood (2013) 122 (21): 5113.

https://doi.org/10.1182/blood.V122.21.5113.5113

Published: 2013

Journal Articles

DNMT3A R882H Overexpression Leads To Hematopoietic and Skin Alterations In Transgenic Mice

Angela M. Verdoni, PhD, Christopher B Cole, Jeffery M. Klco, MD/PhD, Timothy J. Ley, MD

Blood (2013) 122 (21): 479.

https://doi.org/10.1182/blood.V122.21.479.479

Published: 2013

Journal Articles

Graft-Versus-Lymphoma Effect After Non-Myeloablative Allogeneic Transplant Induces Molecular Remission Assessed by High-Throughput Sequencing of T Cell Receptor in Patients with Advanced Stage Mycosis Fungoides and Sezary Syndrome

Wen-Kai Weng, MD, PhD, Randy Armstrong, Sally Arai, MD, Katherine Sutherland, Richard T. Hoppe, MD, Youn H. Kim, MD

Blood (2011) 118 (21): 3114.

https://doi.org/10.1182/blood.V118.21.3114.3114

Published: 2011

Journal Articles

Change in NIH Skin Score 0–3 Correlates with Provider- and Patient-Reported Skin Changes and Overall Survival: Results From the Chronic Gvhd Consortium

David Jacobsohn, MD, Stephanie J. Lee, MD, MPH, Brenda Kurland, PhD, Corey S. Cutler, MD, MPH, FRCPC, Joseph Pidala, MD, MS, Paul A. Carpenter, MD, Shawn Chai, Sally Arai, MD, Mukta Arora, MD, Jeanne Palmer, MD, Paul J. Martin, MD, Steven Z. Pavletic, MD, Mary E.D. Flowers, MD

Blood (2011) 118 (21): 151.

https://doi.org/10.1182/blood.V118.21.151.151

Published: 2011

Journal Articles

How I conduct a comprehensive chronic graft-versus-host disease assessment

Paul A. Carpenter

Blood (2011) 118 (10): 2679–2687.

https://doi.org/10.1182/blood-2011-04-314815

Published: 2011

Journal Articles

Effect of Denileukin Diftitox on Pruritus and Other Skin-Related Symptoms Vs Placebo In Patients with Cutaneous T-Cell Lymphoma

Lauren Pinter-Brown, MD, Anna Kozlovski

Blood (2010) 116 (21): 4922.

https://doi.org/10.1182/blood.V116.21.4922.4922

Published: 2010

Journal Articles

Different Dosage of Bortezomib Impacts the Prevention of Acute Graft-Versus-Host Disease.

Jianyu Weng, MD, Meikun Lü, MD, Xin Du, PhD, Lin Xu, PhD, Suxia Geng, MD, Rong Guo, PhD, Suijin Wu, MD, Wei Ling, PhD, Yuchun Wang

Blood (2009) 114 (22): 4499.

https://doi.org/10.1182/blood.V114.22.4499.4499

Published: 2009

Journal Articles

Clinical, Biological, and Molecular Characteristics of Well-Differentiated Systemic Mastocytosis: a study in 18 Patients by Spanish Network on Mastocytosis (REMA)

Iván Alvarez-Twose, Laura Sánchez-Muñoz, María Jara-Acevedo, Cristina Teodosio, Andrés García-Montero, Mónica García-Cosio, Manuela Mollejo, Alberto Orfao, Luis María Escribano

Blood (2008) 112 (11): 5246.

https://doi.org/10.1182/blood.V112.11.5246.5246

Published: 2008

Journal Articles

Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL).

Madeleine Duvic, Jürgen C. Becker, Stephane Dalle, Francisco Vanaclocha, Maria Grazia Bernengo, Celeste Lebbé, Reinhard Dummer, Samit Hirawat, Lei Zhang, Miriam Marshood, Glen Laird, H. Miles Prince

Blood (2008) 112 (11): 1005.

https://doi.org/10.1182/blood.V112.11.1005.1005

Published: 2008

Journal Articles

A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease

Mary E. D. Flowers, Jane F. Apperley, Koen van Besien, Ahmet Elmaagacli, Andrew Grigg, Vijay Reddy, Andrea Bacigalupo, Hans-Jochem Kolb, Luis Bouzas, Mauricette Michallet, H. Miles Prince, Robert Knobler, Dennis Parenti, Jose Gallo, Hildegard T. Greinix

Blood (2008) 112 (7): 2667–2674.

https://doi.org/10.1182/blood-2008-03-141481

Published: 2008

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

Francine Foss, MD, Madeleine Duvic, MD, Larisa Geskin, MD, Joseph Anderson, MD, Pierluigi Porcu, MD, Raymond J. Hohl, MD,PhD, Maureen Cooper, MD, Jasmine M. Zain, MD, John Zic, MD, Patrica Hibberd, MD,PhD, Mark Acosta, PharmD

Blood (2006) 108 (11): 2712.

https://doi.org/10.1182/blood.V108.11.2712.2712

Published: 2006

Journal Articles

A Randomized Single−Blind Study of Extracorporeal Photopheresis with UVADEX® Plus Conventional Therapy (CT) Compared to CT Alone in Chronic GVHD.

Mary E.D. Flowers, MD, Koen Van Besien, MD, Jane Apperley, MD, Andrea Bacigalupo, MD, Ahmet Elmaagacli, MD, Andrew Grigg, MD, Hans-Jochem Kolb, MD, Luis Fernando Bouzas, MD, Mauricette Michallet, MD, Vijay Reddy, MD, Jim Wang, MD, Paul Williamson, MD, Robert Knobler, MD, Hildegard Greinix, MD

Blood (2006) 108 (11): 758.

https://doi.org/10.1182/blood.V108.11.758.758

Published: 2006

Journal Articles

Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors.

Chitra Hosing, MD, Rima M. Saliba, PhD, Marcos De Lima, MD, Sergio Giralt, MD, Shubhra Ghosh, MD, Yvonne Hsu, Paolo Anderlini, MD, Sharon R. Hymes, MD, Borje Andersson, MD, Issa F. Khouri, MD, Richard Champlin, MD, Daniel Couriel, MD

Blood (2005) 106 (11): 1123.

https://doi.org/10.1182/blood.V106.11.1123.1123

Published: 2005

Journal Articles

Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.

Corey Cutler, MD MPH FRCPC, David Miklos, MD PhD, Stephanie J. Lee, MD MPH, Sook-Bin Woo, DMD, Nathaniel Treister, DMD, Don Bienfang, MD, Lloyd Klickstein, MD PhD, Jesse Levin, BA, Katherine H. Miller, BA, Carol Reynolds, PhD, Mildred Pasek, RN, Vincent Ho, MD, Jerome Ritz, MD PhD, Joseph H. Antin, MD, Robert Soiffer, MD, Edwin Alyea, MD

Blood (2004) 104 (11): 2251.

https://doi.org/10.1182/blood.V104.11.2251.2251

Published: 2004

NARROW

Risk Factors for the Development of Cutaneous Melanoma after Allogeneic Hematopoietic Cell Transplantation

Patterns of Cutaneous Malignancy Risk Among Survivors of Non-Hodgkin Lymphoma Subtypes

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

Role Of Long Pentraxin 3 (PTX3) In Wound Closure Induced By Bone Marrow-Derived Mesenchymal Stromal Cells

A Single Center Experience With Pralatrexate Alone Or In Combination With Bexarotene: Long Term Responses In Advanced Stage Relapsed/Refractory Cutaneous T-Cell Lymphoma

DNMT3A R882H Overexpression Leads To Hematopoietic and Skin Alterations In Transgenic Mice

Graft-Versus-Lymphoma Effect After Non-Myeloablative Allogeneic Transplant Induces Molecular Remission Assessed by High-Throughput Sequencing of T Cell Receptor in Patients with Advanced Stage Mycosis Fungoides and Sezary Syndrome

Change in NIH Skin Score 0–3 Correlates with Provider- and Patient-Reported Skin Changes and Overall Survival: Results From the Chronic Gvhd Consortium

How I conduct a comprehensive chronic graft-versus-host disease assessment

Effect of Denileukin Diftitox on Pruritus and Other Skin-Related Symptoms Vs Placebo In Patients with Cutaneous T-Cell Lymphoma

Different Dosage of Bortezomib Impacts the Prevention of Acute Graft-Versus-Host Disease.

Clinical, Biological, and Molecular Characteristics of Well-Differentiated Systemic Mastocytosis: a study in 18 Patients by Spanish Network on Mastocytosis (REMA)

Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL).

A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

A Randomized Single−Blind Study of Extracorporeal Photopheresis with UVADEX® Plus Conventional Therapy (CT) Compared to CT Alone in Chronic GVHD.

Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors.

Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only